CSPC Pharmaceutical Group (01093): SYS 6077 Injection Approved for Clinical Trial in China

Zhitong Finance APP news, CSPC Pharmaceutical Group (01093) announced that the SYS 6077 injection developed by the group has been approved by China's National Medical Products Administration to issue a drug clinical trial approval notice and can conduct clinical trials in China. The approved clinical indication this time is advanced malignant tumors.